Regulatory Story
Go to market news section View chart   Print
Eden Research plc  -  EDEN   

Notice of Allowance from ARIPO

Released 07:00 09-Oct-2013

RNS Number : 0372Q
Eden Research plc
09 October 2013


Eden Research Plc

("Eden" or "Company")


Notice of Allowance from ARIPO for Yeast Glucan Particles


Eden Research plc (AIM: EDEN), the AIM listed natural micro-encapsulation company, announces that the African Regional Intellectual Property Organisation (ARIPO) has issued a Notice of Allowance for Patent (Application No. AP/P/2006/003845) for Yeast Glucan Particles.


The patent relates to the use of yeast glucan particles as a natural carrier particle for a terpene or combination of terpenes, with or without an additional active substance.


The ARIPO designated states for this application are the following: Botswana, Gambia, Ghana, Kenya, Lesotho, Malawi, Mozambique, Namibia, Sierra Leone, Sudan, Swaziland, Tanzania, Uganda, Zambia and Zimbabwe.


This notice of allowance follows on from the Grant of Patent received earlier in the year from ARIPO for Eden's Plant Bacteria Fungi Formulae, which covers the formulation of more than one terpene selected from a group of four terpenes.


Clive Newitt, Managing Director of Eden comments: "We are delighted to receive a further Notice of Allowance from ARIPO which further strengthens our intellectual property portfolio in Africa.


"Africa has become an increasingly significant market in the worldwide food and crop production sector with a growing amount of the food and other crops (such as cut flowers) being exported to European supermarkets. The increased patent coverage in the ARIPO region ensures that Eden licensees can commercialise products with strong IP protection surrounding the use of Eden's unique technologies."




Eden Research plc  

Clive Newitt, Managing Director

Tel: 01993 862 761

Alex Abrey, Chief Financial Officer

W H Ireland Limited      

Tel: 0117 945 3470

John Wakefield

Walbrook PR Ltd

Tel: 020 7933 8780 or

Paul McManus (Media Relations)

Mob: 07980 541 893

Paul Cornelius (Investor Relations)

Mob: 07827 879 496





Eden is an early stage revenue company with intellectual property and expertise in encapsulation, terpenes and environmentally friendly technologies to provide naturally occurring solutions to the global agrochemicals industry, the animal health industry, and consumer products.


Eden's encapsulation technology harnesses the biocidal efficacy of naturally occurring chemicals produced by plants (terpenes) and can also be used with hydrophobic compounds both natural and synthetic. The technology uses yeast cells to deliver a slow release of natural compounds for agricultural and non-agricultural uses. Terpenes are already widely used in the food flavouring, cosmetic and pharmaceutical industries.


Historically, terpenes have had limited commercial use in the agrochemical sector due to their volatility, phytotoxicity and poor solubility. Eden's platform encapsulation technology provides a unique, environmentally friendly solution to these problems and enables terpenes to be used as effective, low-risk agrochemicals.


With leading consultants in their respective fields, the Company is developing these technologies through innovative research and a series of commercial production, marketing and distribution partnerships.


The Company has a number of patents and has a pipeline of products at differing stages of development targeting specific areas of the global agrochemicals industry. To date, the Company has invested in the region of £12m in developing and protecting its intellectual property. Revenues earned by the Company have been modest whilst the Company has concentrated on securing patent protection for its intellectual property, identifying suitable industrial partners and entering into licence agreements.


Eden was admitted to trading on AIM on 11 May 2012 and trades under the symbol EDEN.


For more information about Eden, please visit 


This information is provided by RNS
The company news service from the London Stock Exchange

London Stock Exchange plc is not responsible for and does not check content on this Website. Website users are responsible for checking content. Any news item (including any prospectus) which is addressed solely to the persons and countries specified therein should not be relied upon other than by such persons and/or outside the specified countries. Terms and conditions, including restrictions on use and distribution apply.


Notice of Allowance from ARIPO - RNS